LKPC(SH:600789) Xi Niu Cai Jing·2025-03-27 10:58Core Viewpoint - Shandong Lukang Pharmaceutical Co., Ltd. reported a revenue of 6.233 billion yuan for 2024, marking a year-on-year increase of 1.41%, while net profit attributable to shareholders surged by 60.30% to 395 million yuan [2][4]. Financial Performance - Revenue for 2024 reached 6.233 billion yuan, up from 6.147 billion yuan in 2023, reflecting a growth of 1.41% [4]. - Net profit attributable to shareholders was 395 million yuan, significantly increasing from 246 million yuan in 2023, representing a growth of 60.30% [4]. - The net profit after deducting non-recurring gains was 209 million yuan, which is a 19.32% increase from 175 million yuan in the previous year [4]. - The net cash flow from operating activities decreased by 33.31% to 403 million yuan compared to 604 million yuan in 2023 [4][5]. - The net assets attributable to shareholders increased by 8.49% to 3.918 billion yuan from 3.612 billion yuan at the end of 2023 [4]. Product and Market Performance - The growth in sales revenue was driven by the enhancement of the "two strongest and six characteristics" product structure, with rapid increases in revenue from diabetes and cardiovascular products [4]. - The company improved its market share, with 16 products ranking first in the domestic market [4]. - International trade also contributed to the overall performance improvement [4]. Non-Recurring Gains and R&D Investment - The increase in net profit was partly due to non-recurring gains from land compensation related to the South District's urban redevelopment, which contributed 152.2 million yuan to asset disposal income [5]. - The company increased its R&D investment to 402 million yuan, achieving technological breakthroughs in innovative drugs, biomanufacturing, and high-end formulations [5]. - The company aims to expand its product lines and strengthen its biomanufacturing sector in the future [5].